Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
Joined January 2018
- Tweets248
- Following243
- Followers1.2K
- Likes55
Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript eur01.safelinks.protection.o…
How can we prevent the aggressive disease course of PTEN loss/inactive cancers? @EmilyGrist1 @ChrisSweens1 eur01.safelinks.protection.o…
AttardLab retweeted
About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.
BREAKING NEWS 📢
Abiraterone has been approved for use on the NHS for men in England with #ProstateCancer that has a high risk of spreading.
Over the next five years, this decision will save the lives of 3,000 men.
➡️ Read more: bit.ly/3NxcMYa
ALT Graphic stating: 'Abiraterone approved for more men in England', with a subtitle '3,000 lives saved in the next five years.'
AttardLab retweeted
Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich
Please follow ecancer.org/en/video/12526-b…
AttardLab retweeted
🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 apccc.org
📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025
✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).
Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini
Ping
@nataliagandur
@bavilima
@yekeduz_emre
AttardLab retweeted
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via apccc.org!
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology
annalsofoncology.org/article…
CAPItello-281
In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor capivasertib to abiraterone and ADT significantly prolonged radiographic progression-free survival with manageable, expected toxicities.
Karim Fizazi
@mdesantis234
@M_SoteloLezama
@Daniel_J_George
@OncoAlert 🚨
@silkegillessen
@AOmlin
@nataliagandur
@bavilima
AttardLab retweeted
@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA – at Berlin, Germany
AttardLab retweeted
CAPItello-281
In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now
With Amplitude trial paving the way, NGS is key in mHSPC
How should we integrate this combo when triplet is already available?
@OncoAlert @myESMO #ESMO25
#ESMO25
Ph III CAPItello 281: Capivasertib + Abiraterone vs pbo + Abi in PTEN-deficient de novo mHSPC
rPFS 33.2 vs 25.7 mo (HR 0.81); OS not yet mature ⚠️
A promising first in class targeted option for this poor-prognosis population
Benefit ↑ w/greater PTEN loss, emphasizing the need for biomarker based 1L treatment as seen with BRCA/HRR @OncoAlert
Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍annalsofoncology.org/article…
AttardLab retweeted
Wonderful discussion by @Prof_Nick_James on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 @myESMO @OncoAlert
STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.
AttardLab retweeted
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
Our latest manuscript with #demichelislab - detailed analysis of ctDNA sequentially collected from metastatic prostate cancer pts receiving cabazitaxel. aacrjournals.org/clincancerr…
🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel.
🧬 cell cycle gene amplification associates with taxane resistance
🤝Results from an international collaborative effort
AttardLab retweeted
Precision medicine enters hormone sensitive prostate cancer therapeutics !
The first of many to follow
💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 nature.com/articles/s41591-0… @AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine @PCF_Science @sloan_kettering
@OncoAlert
💥 First Phase III evidence of PARP inhibition in mCSPC!
🔹 Design: Double-blind, randomized (n=696), HRR+ (56% BRCA1/2)
🔹 Primary endpoint met:
• rPFS HR 0.52 (BRCA) → NE vs 26 mo
• rPFS HR 0.63 (ITT) → NE vs 29.5 mo
🔹 Time to symptomatic progression HR 0.50
🔹 OS (immature): HR 0.79, trend favoring niraparib
🔹 Toxicities: Anemia 29%, Hypertension 27%, manageable
🔹 HRR testing now essential at mCSPC diagnosis
🧠 Clinical impact:
Niraparib + Abiraterone delivers significant PFS improvement in BRCA1/2 mCSPC—marking the PARPi era’s entry into hormone-sensitive disease.
@myESMO @ASCO @UroToday @NatureMedicine @Uromigos
#ProstateCancer #mCSPC #HRR #PARPi #Niraparib #PrecisionOncology #GUOnc #OncoTwitter
